NVSNovartis PharmaceuticalsSigning up patients
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Prostate Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 940 (planned)
- Started
- Jul 1, 2025
- Main results expected
- Sep 29, 2028
- Fully finished
- Nov 4, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Radiographic Progression Free Survival (rPFS)
Measured over: From the date of randomization to the date of the first documented radiographic disease progression using conventional imaging, or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06855277 · record last updated 2026-10-15 · checked 2026-11-09 15:47 UTC